Craig-Hallum analyst Matt Hewitt assumed coverage of NeoGenomics with a Buy rating and $26 price target. The firm says NeoGenomics remains a premier oncology lab testing provider and with the regulatory overhang now removed, it sees an opportunity for the stock to regain its position in growth portfolios.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO: